Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pruritus Chronic Clear all
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching placebo
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
63
States / cities
Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jul 22, 2026, 12:31 PM EDT
Not listed No phase listed Observational

An Observational Study of Pruritus Amongst Hemodialysis Patients

NCT00715260
View directory record Official record
Conditions
Pruritus, Kidney Failure, Chronic, Hemodialysis, Chronic Disease
Interventions
Not listed
Lead sponsor
Acologix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Augusta, Georgia • Metaire, Louisiana • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2008 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab low dose, secukinumab high dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 22, 2026, 12:31 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

NCT04612725
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

NCT02143648
View directory record Official record
Conditions
Uremic Pruritus, Pruritus
Interventions
nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567
View directory record Official record
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 1 Interventional

Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function

NCT02268448
View directory record Official record
Conditions
Cutaneous Nerves CNS Itch
Interventions
Clonidine, Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 22, 2026, 12:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT06736262
View directory record Official record
Conditions
Urticaria Chronic
Interventions
Briquilimab
Drug
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Completed No phase listed Observational

Study of Kids Itch Severity (SKIS)

NCT02672579
View directory record Official record
Conditions
Chronic Pruritus
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
4 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 22, 2026, 12:31 PM EDT
Active, not recruiting Phase 3 Interventional

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View directory record Official record
Conditions
Chronic Pruritus, Atopic Dermatitis
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jul 22, 2026, 12:31 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212
View directory record Official record
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
129
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

NCT03422653
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
57
States / cities
Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Jul 22, 2026, 12:31 PM EDT
Completed No phase listed Observational

A Study of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients

NCT01548716
View directory record Official record
Conditions
Vitamin D Deficiency, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jul 22, 2026, 12:31 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT04210843
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01309737
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

NCT00886795
View directory record Official record
Conditions
Urticaria
Interventions
abatacept (Orencia ®)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Jul 22, 2026, 12:31 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin

NCT05038982
View directory record Official record
Conditions
Prurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo, Skin Diseases
Interventions
Abrocitinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

NCT02143973
View directory record Official record
Conditions
Uremic Pruritus, Pruritus
Interventions
nalbuphine HCl ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Results available

Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Following Burn Injury

NCT01795079
View directory record Official record
Conditions
Burn Injury, Chronic Pain, Pruritus, Itching
Interventions
Transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 22, 2026, 12:31 PM EDT